Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS

Many disease‐related processes occur via protein complexes that are considered undruggable with small molecules. An example is RAS, which is frequently mutated in cancer and contributes to initiation and maintenance of the disease by constitutive signal transduction through protein interaction with effector proteins, like PI3K, RAF and RALGDS. Such protein interactions are therefore significant targets for therapy. We describe a single immunoglobulin variable region domain that specifically binds to activated GTP‐bound RAS and prevents RAS‐dependent tumorigenesis in a mouse model. The crystal structure of the immunoglobulin–RAS complex shows that the variable region competitively binds to the conformationally variant regions of RAS, where its signalling effector molecules interact. This allows the plasma membrane targeted single domain intrabody to inhibit signalling by mutant RAS. This mode of action is a novel advance to directly interfere with oncogenic RAS function in human cancer and shows a universally applicable approach to develop macromolecules to combat cancer. In addition, this method illustrates a general means for interfering with protein interactions that are commonly considered intractable as conventional drug targets.

[1]  S H Kim,et al.  Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. , 1992, Science.

[2]  J. Downward Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.

[3]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[4]  C. Chothia,et al.  The atomic structure of protein-protein recognition sites. , 1999, Journal of molecular biology.

[5]  A. Adjei,et al.  K-ras as a target for cancer therapy. , 2005, Biochimica et biophysica acta.

[6]  C. Fathman,et al.  Targeting Rare Populations of Murine Antigen-Specific T Lymphocytes by Retroviral Transduction for Potential Application in Gene Therapy for Autoimmune Disease1 , 2000, The Journal of Immunology.

[7]  P. Hawkins,et al.  Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. , 2000, Cell.

[8]  T. Rabbitts,et al.  Chromosomal translocation engineering to recapitulate primary events of human cancer. , 2005, Cold Spring Harbor symposia on quantitative biology.

[9]  Catherine L. Worth,et al.  Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery , 2006, Philosophical Transactions of the Royal Society B: Biological Sciences.

[10]  S. Canevari,et al.  Re: Blocking oncogenic Ras signaling for cancer therapy. , 2002, Journal of the National Cancer Institute.

[11]  T. Jacks,et al.  Somatic activation of the K-ras oncogene causes early onset lung cancer in mice , 2001, Nature.

[12]  C. Marshall,et al.  Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation , 1995, Cell.

[13]  T. Rabbitts,et al.  Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies. , 2003, Journal of molecular biology.

[14]  M. Weitzman,et al.  Gene therapy: twenty-first century medicine. , 2005, Annual review of biochemistry.

[15]  John Mendelsohn,et al.  The EGF receptor family as targets for cancer therapy , 2000, Oncogene.

[16]  G. Stamp,et al.  RalGDS is required for tumor formation in a model of skin carcinogenesis. , 2005, Cancer cell.

[17]  C. Der,et al.  Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[18]  I. Vetter,et al.  The Guanine Nucleotide-Binding Switch in Three Dimensions , 2001, Science.

[19]  W. Kolch Coordinating ERK/MAPK signalling through scaffolds and inhibitors , 2005, Nature Reviews Molecular Cell Biology.

[20]  T. Rabbitts,et al.  Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. , 2002, Journal of molecular biology.

[21]  H. Varmus,et al.  Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. , 2001, Genes & development.

[22]  R. Weinberg,et al.  Species- and cell type-specific requirements for cellular transformation. , 2004, Cancer cell.

[23]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[24]  J. Navaza,et al.  AMoRe: an automated package for molecular replacement , 1994 .

[25]  T. Rabbitts,et al.  Selection of antibodies for intracellular function using a two-hybrid in vivo system. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Phillip T. Hawkins,et al.  Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ , 2000, Cell.

[27]  M. Engelhard,et al.  Transient kinetic studies on the interaction of Ras and the Ras-binding domain of c-Raf-1 reveal rapid equilibration of the complex. , 1998, Biochemistry.

[28]  A. Adjei,et al.  Blocking oncogenic Ras signaling for cancer therapy. , 2001, Journal of the National Cancer Institute.

[29]  M Geyer,et al.  Three-dimensional structures and properties of a transforming and a nontransforming glycine-12 mutant of p21H-ras. , 1994, Biochemistry.

[30]  E. Goldman,et al.  A mutational analysis of binding interactions in an antigen-antibody protein-protein complex. , 1998, Biochemistry.

[31]  S. Biocca,et al.  Evidence for proteasome dysfunction in cytotoxicity mediated by anti-Ras intracellular antibodies. , 2003, European journal of biochemistry.

[32]  V. Torchilin Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[33]  P. Seeburg,et al.  Biological properties of human c-Ha-ras1 genes mutated at codon 12 , 1984, Nature.

[34]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[35]  T. Rabbitts,et al.  Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation , 2003, The EMBO journal.

[36]  T. Rabbitts,et al.  The LIM‐only protein Lmo2 is a bridging molecule assembling an erythroid, DNA‐binding complex which includes the TAL1, E47, GATA‐1 and Ldb1/NLI proteins , 1997, The EMBO journal.

[37]  R. Weinberg,et al.  Isolation of a transforming sequence from a human bladder carcinoma cell line , 1982, Cell.

[38]  C. Kiel,et al.  The Activation of RalGDS Can Be Achieved Independently of Its Ras Binding Domain , 2002, The Journal of Biological Chemistry.

[39]  L. Chin,et al.  Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.

[40]  M. Matsushita,et al.  Protein transduction technology , 2005, Journal of Molecular Medicine.